Programa científico dedicado al trastorrno bipolar del 26 th ECNP Congress 2013

1.
Programa Científico
con las actividades del 26 ECNP Congress
dedicadas al trastorno bipolar
C.08: Bipolar disorder: the evolving story
Educational financial support provided by AstraZeneca
Sunday 16:45 - 18:30
Room: Room J
Chair
Roger McIntyre, Canada
Presentations
C.08.01: Improving patient outcomes in bipolar disorder
Eduard Vieta, Spain
C.08.02: A disease for life? Beyond acute episodes in bipolar disorder
Guy Goodwin, United Kingdom
Session Type
Satellite symposium

2.
C.13: The multidimensional perspective of Bipolar I
disorder
Educational financial support provided by H. Lundbeck A/S
Monday 16:45 - 18:30
Room: Room M2
Chair
Andrea Fagiolini, Italy
Presentations
C.13.01: The manic depressive spectrum, the DSM5 perspective
Andrea Fagiolini, Italy
C.13.02: Bipolar mixed states, recognition and course
Allan H. Young, United Kingdom
C.13.03: Treatment of mixed states
Michael Berk, Australia
Session Type
Satellite symposium
CA.01: Bipolar treatment café
Sunday 16:10 - 16:40
Room: Outside Auditorium
Session Type
Scientific Café

3.
S.05: An update on the psychopharmacology of bipolar
disorder
Pharmacological treatment of bipolar disorder may change depending on
the illness phase and needs to be specifically tailored for each patient.
Moreover, due to the complexity and multidimensional nature of bipolar
illness, a treatment regimen which ensures a sustained long-term
response may require using a combination of many drugs. A variety of
guidelines exist for bipolar disorders, covering both management of
acute mood episodes and long-term prophylaxis; the majority of them
include lithium in their recommendations for first-line maintenance
therapy. Divalproex, lamotrigine and sometimes olanzapine are also
included as other first-line maintenance therapies. Certainly, there have
been many developments in the field of bipolar disorder, including new
placebo-controlled trials assessing not only traditional maintenance
therapies, but also newer options such as aripiprazole, long-acting
risperidone, olanzapine, oxcarbazepine, quetiapine, ziprasidone,
asenapine and cariprazine. The risk-benefit ratio associated with AD use
in BD remains unclear. Hence, it is important to ascertain, as far as
possible, how to best use these drugs through the evaluation of factors
supposedly involved in the outcomes of AD treatment in BD. The
rationale for holding this symposium stems from the need to translate
the accumulated psychopharmacological evidence of bipolar disorders
into a useful guide for clinical practice.

4.
Sunday 14:30 - 16:10
Room: Auditorium
Chairs
Eduard Vieta, Spain
Aysegül Yildiz, Turkey
Presentations
14:30-14:55
S.05.01: Lithium: still a cornerstone in the long-term treatment of
bipolar disorder?
Willem A. Nolen, The Netherlands
14:55-15:20
S.05.02: New developments in the pharmacotherapy of bipolar disorders
Joseph R. Calabrese, USA
15:20-15:45
S.05.03: Atypical antipsychotics in bipolar disorder and schizophrenia:
similarities and discrepancies
Stefan Leucht, Germany
15:45-16:10
S.05.04: The role of antidepressants in bipolar disorder
Isabella Pacchiarotti, Spain
Session Type
Symposium
Track
Clinical Treatment track

5.
S.11: Epigenetics: challenging new findings in
psychiatry
Epigenetic regulation is known to be involved in several psychiatric
disorders, especially in stress-related disorders, Alzheimer disease, and
alcohol related diseases. Although epigenetics is a relatively new area of
biological psychiatry, both animal model and human studies on the role
of transcriptional programs in cell fate decisions in response to stress
environment are becoming increasingly popular. Epigenetic differences
have been found in post-mortem brains of people with a major
depressive disorder. Recent studies also suggest that DNA methylation at
certain neurotransmitter gene sites may be involved in alcohol
dependence and there are now encouraging findings in Alzheimer
research. This symposium will discuss the epigenetic regulation involved
in stress-related disorders, Alzheimer disease, or Fetal Alcohol
Syndrome. The symposium aims to foster advancements in behavioural
epigenetics and improve understanding of the fundamental mechanisms
that shape individual vulnerability and resilience to adverse behavioural
outcomes.

6.
Monday 09:00 - 10:40
Room: Room F
Chair
Laurence Lanfumey, France
Presentations
09:00-09:25
S.11.01: Epigenetics in ageing and Alzheimer's disease
Daniel L. A. Van Den Hove, The Netherlands
09:25-09:50
S.11.02: Epigenetic control of stress-induced gene transcription and
behaviour: relevance to PTSD
Johannes M.H.M. Reul, United Kingdom
09:50-10:15
S.11.03: Epigenetic implications in schizophrenia, bipolar disorder and
autism
Hamid Abdolmaleky, USA
10:15-10:40
S.11.04: Heat shock factors and epigenetics in the fetal alcohol
syndrome
Valerie Mezger, France
Session Type
Symposium
Track
Interface Research track

7.
S.12: New targets for treating depression and anxiety:
preclinical and clinical studies
Monday 09:00 - 10:40
Room: Room J
Chair
Nicoletta Brunello, Italy
Presentations
09:00-09:12
S.12.01: Identification of a significant role for the ventral hippocampus in
neuropeptide S-elicited anxiolysis
Irina Ionescu, Germany
09:12-09:24
S.12.02: Histaminergic regulation of presumed serotonin neurons in the
dorsal raphe nucleus
Kara Panetta, United Kingdom
09:25-09:37
S.12.03: Effect of early life experiences on brain structure and function:
neurogenesis and decision making
Manila Loi, The Netherlands
09:37-09:49
S.12.04: Targeting postsynaptic density protein 95(PSD-95)/Discs
large/Zonula occludens-1 (PDZ)-interactions of the glutamatergic
synapse in animal models of depression
Florian Freudenberg, Germany
09:50-10:02
S.12.05: Serotonin regulates hippocampal synaptic plasticity and object
memory in mice
Sebastian Fernandez, France
10:02-10:14
S.12.06: Corticotropin releasing hormone and serotonin - the
neuropsychopharmacology of fear learning deficit from rodents to
humans

8.
Ivo Heitland, The Netherlands
10:15-10:27
S.12.07: Role of 5-HT1A/5-HT2A receptors interaction in the severity of
depression and antidepressant response
Gaël Quesseveur, France
10:27-10:39
S.12.08: Lithium-regulated genes in peripheral cell models of bipolar-
affective patients
Sarah Kittel-Schneider, Germany
Session Type
Junior Scientists symposium
Track
Preclinical Research track

9.
S.15: Immunogenetics and psychiatric disorders
This symposium deals with the question whether immune mediated
tissue injury of the brain in early life may increase the susceptibility for
developing schizophrenia or bipolar disorders. It will review evidence for
a genetic association between genes coding for immune related
molecules and the incidence of the respective psychiatric disorders. It will
discuss the effect of childhood maltreatment on stress related
immunological abnormalities and their possible relevance for brain
development and function. Similarly the influence of early life infections
of the central nervous system on the development of psychiatric
disorders later in life will be reviewed. Finally, a new concept will be
discussed, suggesting that infection or immune responses in the central
nervous system induces the expression of antigens, encoded by
endogenous retroviruses of the HERV-W family, which have been shown
before to amplify pro-inflammatory and neurotoxic cascades. Such a
mechanism may provide a pathogenetic link between genetic and
environmental factors operating in increasing the susceptibility for
schizophrenia and bipolar disease.

10.
Monday 14:30 - 16:10
Room: Room F
Chairs
Eero Castrén, Finland
Marion Leboyer, France
Presentations
14:30-14:55
S.15.01: Immunogenetics: a molecular approach to the modulation of
emotion and cognitive processes
Bernhard T. Baune, Australia
14:55-15:20
S.15.02: Childhood maltreatment and the course of depression: the role
of inflammation
Andrea Danese, United Kingdom
15:20-15:45
S.15.03: Immunogenetic background in schizophrenia and bipolar
disorder
Ryad Tamouza, France
15:45-16:10
S.15.04: Role of Human Endogenous Retroviruses (HERVs) in psychotic
disorder
Hervé Perron, Switzerland
Session Type
Symposium
Track
Interface Research track

11.
S.25: Genetic implications in bipolar disorder
Studies focused on genetic factors involved in both the response to drugs
prescribed in bipolar patients and their side effects, would not only
increase the quality of prescriptions, but also would contribute to a better
understanding of the aetiology and the heterogeneity of bipolar disorder.
Results from genetic studies could also bring us new biological tools that
may optimize the detection of high-risk populations, such as suicidal
patients. The aim of this symposium is to provide an update on most
recent results from genetic studies, including pharmacogenetics. The
topics of this symposium will be focused on recent results from
pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug
treatment. In the second presentation, molecular data that differentiates
lithium responders from non-responders will be discussed. Results from
an on-going exon sequencing study, investigating the genetics of lithium
responsive families, will also be exposed. Regarding pharmacogenetics of
side effects in bipolar disorder, data from studies focused on the genetic
variants that could influence the emergence of antipsychotic induced
extrapyramidal symptoms, will be analysed. Lastly, recent results
concerning the possible association between genetic variability at
pathways involved in the mechanism of action of lithium and the
emergence of suicidal behaviour in bipolar disorder will be presented.

12.
Wednesday 09:00 - 10:40
Room: Auditorium
Chair
István Bitter, Hungary
Presentations
09:00-09:25
S.25.01: Pharmacogenetics of antidepressant, antiepileptic and
neuroleptic drug treatment
Leif Bertilsson, Sweden
09:25-09:50
S.25.02: Molecular genetic aspects to serotonergic drugs in bipolar
disorder
Xenia Gonda, Hungary
09:50-10:15
S.25.03: Pharmacogenetics of efficacy and treatment side effects in
bipolar disorder
Alessandro Serretti, Italy
10:15-10:40
S.25.04: Genetics of suicidal behaviour in bipolar disorder: an update
Antoni Benabarre, Spain
Session Type
Symposium
Track
Clinical Treatment track